SCHEMBL7247352

SCHEMBL7247352

CC(C)(Oc1ccc(C(=O)c2ccccc2Cl)cc1)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 13/20 0.67
PPARA Q07869 12/20 0.67
FABP2 P12104 2/20 0.67
SLC22A12 Q96S37 1/20 0.67
KMT2A Q03164 4/20 0.64
CYP2C19 P33261 3/20 0.58
MEN1 O00255 3/20 0.58
CYP1A2 P05177 2/20 0.58
CYP3A4 P08684 2/20 0.58
MAPT P10636 2/20 0.58
CYP2D6 P10635 1/20 0.58
PPARD Q03181 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 2/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11441192 0.83 PPARG (0.76) PPARGPPARAFABP2SLC22A12KMT2A
SCHEMBL11400050 0.83 PPARG (0.70) PPARGPPARAFABP2SLC22A12KMT2A
SCHEMBL11061399 0.81 KMT2A (0.65) KMT2AMAPTTDP1KDM4E
Fenofibric Acid SCHEMBL16377 0.80 PPARA (1.00) PPARGPPARAFABP2SLC22A12KMT2A
Fenofibric Acid SCHEMBL28478335 0.79 PPARA (0.97) PPARGPPARAFABP2SLC22A12KMT2A
Fenofibric Acid SCHEMBL10967778 0.79 PPARA (0.97) PPARGPPARAFABP2SLC22A12KMT2A
SCHEMBL11578249 0.79 KMT2A (1.00) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL28033215 0.79 KMT2A (0.71) KMT2AALDH1A1TDP1POLB
SCHEMBL10489212 0.78 KMT2A (0.75) KMT2AMAPTALDH1A1TDP1POLB
Fenofibric Acid SCHEMBL4756701 0.78 PPARA (0.94) PPARGPPARAFABP2SLC22A12KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030119757-A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) SCHERING CORPORATION 2003-06-26 US disclosed
EP-0012804-B2 Salts of a non toxic, activated anion exchange resin capable of establishing a stable binding with bile acids and 2-(4'-(p-chlorobenzoyl)-phenoxy)-2-(methyl)-propionic acid and pharmaceutical compositions comprising these salts ALFA FARMACEUTICI S.p.A. (IT) 1987-03-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119757-A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) FABP2, CETP, PCSK9 PPARG 482/4885PPARA 501/4885FABP2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.